for you call. financial and conference TRACON's second will recent our pipeline begin with activities. thank results and quarter business and afternoon, joining Good on update I XXXX an updated
Finance, six Following for Scott ended Vice that, of Brown, results and President our XXXX. the review XX, three months will June financial our
we conclude Finally, will questions. by taking your
be Our efforts on continue propositions. to centered three value
we pipeline assets. First, develop to continue a of clinical robust stage
assets follow with XXXX. clinical we the IMF's antibodies development progress of with pipeline these of intent of Second, least for interest preclinical at biospecific great in multiple selecting the of one
external U.S. to independent shareholder believe CO expertise. our partnerships clinical assets continue value. and our key significant establish includes to [ph] our that to allow development we will evaluate will new that long-term potentially commercialization pipeline drive platform stage continue add Third, to platform us leverage to product We product development additional
combination of begin do improved a with Let's pathways, a substantial VEGF our that essential VEGF the endoglin majority agents ophthalmic experience in target with update in first not formulation inhibitors inhibitors angiogenetic with like of on believe wet vision the Because AMD. be upon asset, there is stage meaningfully carotuximab. clinical brief treatment we DE-XXX, single-agent patients developed opportunity for to
with doses that that combined Lucentis treatment single-agent three-arm Phase study randomized last DE-XXX compares treatment Our the with licensee, different II two Santen, they completed to week in enrollment Lucentis. announced with AVANTE of
of on data, developmental, primary high significant in global the rights sites commercialization acuity patients to low DE-XXX, U.S. in accrued [ph] remaining months regulatory, and first-half of a endpoint royalty and XXXX. top at expected including line corrected the teen of are including six following single-digit The $XXX in TRACON retains milestones, to and visual dosing net phased XX the sales. million financial success best trial
We'll a lung chemotherapeutics. of TRCXXX, Phase on or is DNA sponsored pathway second focused continues reverse turn Phase certain to stage in cell clinical inhibitor repair cancer. non-small base small-molecule that four by that excision NCI is now I resistance the Enrollment our intended II that patients to asset the trials with to novel are
collaborators goal a specimens in II biomarkers academic Phase as profile in glioblastoma protein specimens identify treated well trial, TRCXXX with evaluate continue to a being tumor from to from gene correlates or tumor patients the in as their with expression ongoing Our trials, completed response. that
the I Phase TRCXXX, patients sites Proceedings, Moving in we the asset II that data with clinical studying in in on the patients the enroll at Phase II to continue to U.S. in in prostate stage portion of our and were Phase we're cancer, published third trial trial ASCO the XX
are We cohorts. three enrolling patients in
first FXXXL with The mutation. receptor patients angio includes a
evidence another in second defined Phase I mutation the of the of was on portion completed potential with patients based identified efficacy The consists that study. of point
with patients Xtandi to for another of consists Orlita. bases third The resistance or
up receive this right their II proof they CDXX TJXXXX, sales. in, does if asset. week, initial following concept Phase to opt and Phase clinical we in low-single-digit royalty on reacquire not to TRACON million independently. second-half a making We asset Janssen of and in milestones a If can study licensed million line II of TRACON dosing $XX X stage announced fourth Last advance TRCXXX $XXX study antibody to from Janssen, the success-based upfront TRACON data Phase data, a our from expect XXXX. exercise entitled top is in the TRCXXX the of payment
collaboration TJXXXX We with first our them. biopharma to in agreement I-Mab with developing are
tri-centric, in in and may clinical a escalating presenting If TJXXXX we to and the Europe, development and antibody in to the royalty top payments this with a both as license X China. In dose Roche. that they anticipate the outside non-royalty be of and enrollment if receive being XXXX. by is is from TJXXXX marketed sales of will entitled would collaboration receive single U.S. for antibody, Phase the of TJXXXX data We out this to and I-Mab commercializes and I-Mab regulatory responsible Greater in elect PDL-X combination line is third-party. a portions trial royalties and completing TRACON agent TRACON net
assets with are believe a multi-product second We in antibodies to multi-product including a critical time of is in pipeline cancer accessed seven bispecific as target. collaboration PDL-X for this TRACON. our of disclosed these to five most second Our a through therapy has differentiator bispecific addition approaches compelling a developing North I-Mab you antibodies I-Mab five the target I-Mab of with treatment to that a bispecific At agreement for antibodies one that to America. and I-Mab's collaboration develop exciting up therefore,
With ILX, the being target BXHX second CDXX, or CDXX, XXBB. either
any also equally antibodies TRACON becomes commercialization. the I-Mab the U.S. this in-license to collaboration, In will U.S. trials. bear in cost TRACON an share the profits any advanced U.S. will agreement, to antibody bispecific of study. cost the development time subject right For to and will and two from at early clinical in for the of lead share bispecific I-Mab And commercialization the stages has the and and development of that companies clinical pivotal more TRACON prior of phase opting conclusion from each also commercialization.
escalate the this our including of opt-in phase reflect Greater option of development. expand outside would Exercising all rights advancing payments territories The China. to
prior million example, its payment exercises IND to TRACON due to enabling studies. $XX opt-in option of is For an
the our U.S. IND bispecific antibody for We in in file expect I-Mab from first to an XXXX.
TRACON risk ex-U.S. that profit collaboration As the a inspire I-Mab, in through commercialization U.S. for model. preferred and and solution select clinical a believe we with companies can cost share become development
of We're need development for sharing platform, also and a costs of contracting and and appreciate the decreases shortens capability creates development and U.S. potential quality the leverage product enhances from the get that and believe development our timelines. without the We to ability eager product to possess clinical with this using partners our trials the the CRO, the commercialization. further clinical cost risk development alignment value model drug strong profits who to substantially
new believe assets to development assets. and product accessing capacity which best-in-class TRACON first-in-class, time companies at stage capital we from develop identify with have clinical and efficient a fast-forward benefit this efforts U.S. stage clinical We platform, solution. rapid the our continue we offers development ex-U.S. drug to We would or
offset of developing product. a a Johnson As was the a incremental with deal new could equity partner include the prior expense licensed to with Johnson, case an & collaboration investment our from
and multiple financial a capital our potential operations to expected creating milestones. fund From quarter resources bad through currently our planned third perspective, are to be the of XXXX, into sufficient
time, provide will this on At update our an financials. Scott
